A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors (NCT06234423)
A Phase 1, First-in-Human Study of CUSP06, a Cadherin-6 (CDH6)-Directed Antibody-Drug Conjugate, in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.
Who can join: Review the eligibility criteria below.
Location: Sarah Cannon Research Institute at HealthONE — Denver, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- Sarah Cannon Research Institute at HealthONE — Denver, Colorado
- Yale University — New Haven, Connecticut
- Mount Sinai Medical Center — Miami Beach, Florida
- Florida Cancer Specialists — Sarasota, Florida
- Dana Farber Cancer Institute — Boston, Massachusetts
- START Midwest — Grand Rapids, Michigan
- NYU Cancer Institute Clinical Cancer Center — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Stephenson Cancer Center — Oklahoma City, Oklahoma
- SCRI Oncology Partners — Nashville, Tennessee
- MD Anderson Cancer Center — Houston, Texas
- NEXT Oncology — Houston, Texas
- START San Antonio — San Antonio, Texas
- NEXT Oncology — Fairfax, Virginia
- Mater Cancer Care Centre — South Brisbane, Queensland
📞 Contact the Study Coordinator
Phone: (610) 256-5979
Email: Priya.Marreddy@oncusptx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ovarian Cancer
- Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy — New York, New York
- Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer — Pittsburgh, Pennsylvania
- Trial on Radical Upfront Surgery in Advanced Ovarian Cancer — New York, New York
- Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) — Duarte, California
- Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) — Little Rock, Arkansas
- NeoVax With Nivolumab in Patients With Ovarian Cancer — Boston, Massachusetts
Explore by condition: All Ovarian Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.